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Abstract  
Myotonic dystrophy type 1(DM1), the most common form of adult-onset muscular dystrophy, is caused 
by an expanded (CTG)n repeat in the 3’ untranslated region (UTR) of the DM protein kinase (DMPK) 
gene.  The toxic RNA transcripts produced from the mutant allele alter the function of RNA binding 
proteins leading to the depletion of muscleblind-like (MBNL) proteins and an increase in steady state 
levels of CUG-binding protein 1 (CUGBP1).  The role of increased CUGBP1 in DM1 pathogenesis is 
well studied using genetically engineered mouse models.  However, the effect of reduction of CUGBP1 is 
not clear yet.  In this study, we generated CUGBP1 knockout mice, which also carry an inducible toxic 
RNA transgene to test the effects of CUGBP1 reduction in RNA toxicity.  We found that while absence 
of CUGBP1 did not correct splicing defects, it did however mitigate the increase in translational targets of 
CUGBP1 (MEF2A and CEBPβ).  Notably, we found that loss of CUGBP1 prevented deterioration of 
muscle function by the toxic RNA, and resulted in better muscle histopathology.  These data suggest 
reduction of CUGBP1 may be beneficial to the muscular dystrophy associated with RNA toxicity.   
 
 
Introduction 
Myotonic dystrophy type 1 (DM1) is the most common cause of the adult-onset muscular dystrophy with 
an incidence of 1 in 8000 and is a multi-systemic disorder (1).  Major features of this autosomal dominant 
disorder are myotonia, muscle weakness, atrophy, smooth muscle dysfunction, cardiac defects and insulin 
resistance (2).  DM1 is triggered by the expanded (CTG)n triple repeat in the 3’-untranslated region 
(UTR) of the DMPK gene (1).  This is transcribed to produce mutant RNAs containing CUG repeats that 
are retained in the nucleus to form RNA foci (3, 4).  This affects the nuclear and cytoplasmic activities of 
RNA binding proteins such as muscleblind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1) (5-8). 
MBNL1 binds to the expanded CUG repeat and co-localizes with the RNA foci, causing a local reduction 
of MBNL1 (6, 7).  Consequently, the activity of MBNL1 as a splicing regulator is impaired, resulting in 
aberrant alternative splicing of target genes (9).  Consistent with the loss of MBNL1 function, an analysis 
of MBNL1 knockout mice (MbnlE3/E3) showed that these mice developed some of the characteristic 
features of DM1, including misregulated mRNA splicing, muscle histopathological changes, cataracts, 
and myotonia (10).  Moreover, an adenoviral delivery of MBNL1 reversed the splicing changes and 
myotonia, again underscoring the importance of MBNL1 in the DM1 disease phenotype (11). 
 
In addition to MBNL1, CUGBP1, a member of CUG-BP and ETR-3-like factor (CELF) family, is 
implicated in the disease process.  CUGBP1 has been reported to have multiple functions in RNA 
metabolism including regulation of alternative splicing, RNA stability and translational regulation of its 
RNA targets (12-16).  The mutant DMPK transcript is thought to activate PKC activity, leading to a 
hyperphosphorylation of CUGBP1 (17), resulting in the stabilization of and increased steady state levels 
of CUGBP1 in DM1 skeletal muscle and heart tissues.  Transgenic mice over-expressing CUGBP1 
showed neonatal lethality, skeletal muscle histological changes, and misregulated splicing pattern 
observed in DM1 patients (18, 19).  Heart specific over-expression of CUGBP1 caused premature 
lethality, histopathological and echocardiographic abnormalities, and splicing defects (20).  Two different 
transgenic mouse models which over-expressed CUGBP1 in skeletal muscle developed DM1 features.  
One mouse model showed that CUGBP1 responsive alternative splicing events were misregulated in 
skeletal muscle and that CUGBP1 affects muscle integrity and function (21).  In the other model, 
muscular dystrophy, fiber type switching, and delayed muscle development were seen in conjunction with 
increased levels of p21 and MEF2A (both of which are translational targets of CUGBP1) (18).  Both of 
these models exhibited muscle loss, impaired muscle function and dystrophic muscle histology.  These 
data demonstrate that increased CUGBP1 contributes to DM1 pathogenesis and suggests that reduction of 
CUGBP1 in a DM1 mouse model may have beneficial effects.   
 
To test this, we generated CUGBP1 knockout mice that also carried an inducible toxic RNA transgene (5-
313) (22).  We found muscle function in these double transgenic mice was protected and the 
histopathological features were milder as compared to mice carrying only the toxic RNA transgene, 
despite the fact that many alternative splicing events known to be mis-regulated in DM1 were not 
corrected by the absence of CUGBP1.  This was associated with decreased Nkx2-5 levels in skeletal 
muscle from Cugbp1-/- mice expressing the toxic RNA, and corresponded to the milder histopathology of 
the muscle in these mice.  Additionally, the protein levels of MEF2A and C/EBP were reduced in the 
absence of CUGBP1.  These data suggest reduction of CUGBP1 may be beneficial to the muscular 
dystrophy associated with DM1. 
 
 
Results   
Levels of CUGBP1 correlate with skeletal muscle histopathology in DM1. 
We first evaluated CUGBP1 levels in skeletal muscles from patients with DM1.  Western blot analyses of 
muscle extracts showed increased CUGBP1 (up to 5 fold) that correlated well with muscle histopathology 
(Fig. 1A).  Next, we investigated CUGBP1 in a doxycycline inducible RNA toxicity mouse model of 
DM1 (5-313), which expresses an eGFP gene fused to the DMPK 3’UTR (CTG)5 (22).  CUGBP1 was 
increased by induction of toxic RNA (between 1.5 to 5 fold) and the expression was highest in the 
muscles with the most severe histopathology (Fig. 1B).  Thus the mouse model accurately represented 
these aspects of the disease phenotype providing a basis for further investigations. 
 
Absence of CUGBP1 does not affect MBNL1 or CUGBP2 in mice with RNA toxicity. 
To determine whether reduction of CUGBP1 will improve the muscle pathology, 5-313 mice were 
crossed to Cugbp1-/- mice to generate Cugbp1-/-/5-313+/- mice and Cugbp1-/-/5-313+/+ mice.  The ratio of 
+/+, +/- and -/- Cugbp1 mice was different from the expected 1:2:1 Mendelian ratio at 21 days after birth 
(+/+: +/-: -/- = 24: 62: 14, P < 0.0001, 2 test).  This result is very similar to a previous Cugbp1-/- mice 
study (23).  Cugbp1-/- mice were weak and developed cataracts (Supp. Fig. S1).  Both Cugbp1-/-/5-313+/- 
and Cugbp1-/-/5-313+/+  were induced to express the toxic RNA using 0.2% doxycycline delivered in the 
drinking water for 5 months and 2 weeks, respectively.  Cugbp1+/+/5-313 induced (+dox) and the 
appropriate uninduced (-dox) controls were also utilized.  First, we analyzed the expression of Cugbp1 by 
qRT-PCR (Supp. Fig. S2A) and western blot (Fig. 2) to ensure knockout mice did not express any 
CUGBP1.  Cugbp1+/+/5-313 control mice expressed 2-3 fold more CUGBP1 after the induction of toxic 
RNA, whereas CUGBP1 was not detected in Cugbp1-/-/5-313 mice even after induction (Fig. 2).  
Induction of the transgene was confirmed by qRT-PCR (Supp. Fig. S2B) and western blot for eGFP (Fig. 
2).  
 
We tested whether any of the other CELF proteins compensated for the absence of CUGBP1.  The level 
of Cugbp2 expression was determined using qRT-PCR (Supp. Fig. S2C) and western blot (Fig. 2).  Both 
Cugbp2 mRNA and protein levels of CUGBP2 were unaffected by the absence of CUGBP1 and the 
presence of toxic RNA.  We also performed qRT-PCR to quantify the levels of Celf4 expression and 
found it was not expressed in skeletal muscle (data not shown).  MBNL1 protein levels were assayed by 
western blot.  Neither RNA toxicity nor the absence of CUGBP1 changed the levels of total MBNL1 
protein in this mouse model (Fig. 2). 
 
Absence of CUGBP1 preserves muscle function in the presence of RNA toxicity 
To analyze muscle function, we have established treadmill running and grip strength tests.  Cugbp1-/-/5-
313 mice were weak even in the absence of toxic RNA.  Furthermore, induction of RNA toxicity by 
doxycycline administration in 5-313+/+ mice made them much weaker leading to difficulties measuring 
the muscle function such as running and grip strength.  Due to the severity of this animal model, Cugbp1-/-
/5-313+/- mice, which developed a milder disease phenotype, were used instead and tested for grip 
strength and their ability to complete a 752 meter forced run.  After 5 months, the Cugbp1+/+/5-313+/- 
uninduced (-dox) group retained 99% of their run ability and 88.2% of their forelimb grip strength 
compared to their baseline function, whereas Cugbp1+/+/5-313+/- induced for 5 months with continued 
doxycycline administration (+dox) mice decreased to 83.6% and 75.9%, respectively (Fig. 3A, B) (p < 
0.05).  Cugbp1-/-/5-313+/- uninduced (-dox) mice retained only 31.3% of their run ability and 77.5 % of 
their grip strength compared to their baseline function.  However, the Cugbp1-/- mice expressing the toxic 
RNA maintained their run ability (29.9%) and their grip strength (82.1%) (Fig. 3A, B).  Thus unlike the 
RNA toxicity mice expressing CUGBP1 where we observed a significant decrease in function, the loss of 
CUGBP1 resulted in a preservation of muscle function in the 5-313 +/- transgenic mice with RNA toxicity.  
We also examined cardiac function by ECG and myotonia using EMG.  Both Cugbp1+/+ and Cugbp1-/- 
mice developed prolonged PR intervals on the ECG and myotonia by two weeks after induction.  (Supp. 
Table S1).  Absence of CUGBP1 did not improve the cardiac conduction defects or myotonia, in the 
induced Cugbp1-/- /5-313 +/- mice.   
 
Absence of CUGBP1 does not correct misregulated alternative splicing. 
Misregulation of developmental alternative splicing transitions is a characteristic molecular feature of 
DM1, and CUGBP1 is known to play an important role in alternative splicing (6, 19, 24-26).  Some of the 
splicing targets are antagonistically regulated by MBNL1 and CUGBP1 while others are specific to 
MBNL1 or CUGBP1 (13, 27).  To determine whether the removal of CUGBP1 restores the missplicing 
events affected by the toxic RNA, we analyzed various splicing targets which are abnormally spliced in 
the 5-313+/+ model.  Aberrant splicing of Clcn-1 exon 7 is a key feature of DM1 and responsible for 
myotonia (28, 29).  Both Cubgp1+/+ and -/- mice showed misregulation of Clcn-1 splicing in the presence 
of toxic RNA (Fig.  4A).  Additionally Tnnt3 exon F (the fetal isoform) and Smyd1 exon 39 were 
misregulated in skeletal muscle from both induced +/+ and -/- mice (24, 30, 31) (Fig.  4A).  Splicing 
targets reported to be CUGBP1 specific (Nrap exon 12 and Fxr1h exon 15, 16) were also examined and 
found to be misregulated by toxic RNA in both the +/+ and -/- mice (13, 21, 32-34) (Fig.  4B).  In 
summary, the alternative splicing events that are misregulated in this RNA toxicity model were not 
rescued by knockout of CUGBP1. 
 
Interestingly, we found that the absence of CUGBP1 lead to a more embryonic pattern in all splicing 
events compared with mice expressing CUGBP1, even in the absence of toxic RNA (Fig. 4A, B). 
To determine if the muscle from Cugbp1-/- mice is in an earlier embryonic/developmental stage, we 
looked at the expression of embryonic myosin heavy chain (Myh3) by qRT-PCR.  Cugbp1-/- mice have 
3.6 fold (P < 0.05) more Myh3 than Cugbp1+/+ mice in the absence of RNA toxicity and in the absence of 
any active degeneration/regeneration process (Fig. 4C).  This is consistent with a more developmentally 
immature muscle.  The levels increased to 6.7 fold after induction of RNA toxicity (Fig. 4C), like the 
responses seen in mice with CUGBP1.  These data suggest that CUGBP1 is not as strong a splicing 
modulator in RNA toxicity, and that other factors affected by toxic RNA (e.g.  MBNL1) may have a 
greater impact on the splicing events. 
 
Absence of CUGBP1 leads to better muscle histology. 
Hematoxylin and eosin staining were performed on quadriceps muscles from Cugbp1+/+/5-313 and 
Cugbp1-/-/5-313 mice.  These muscles were graded according to a histopathology scoring system we have 
developed in the lab.  Both uninduced Cugbp1+/+ and -/- mice showed normal muscle histology with 
peripherally located nuclei and uniform fiber size (Fig. 5A).  Atrophic fibers and inflammation were not 
observed in these muscles.  By 2 weeks on 0.2% dox induction, Cugbp1+/+/5-313+/+  mice had 
characteristic DM1 histological feature including increased central nuclei, variation in fiber size and 
nuclear clumping (Fig. 5A), as described previously (22).  Their resulting average scores fell within the 
moderate severity range (Fig. 5B).  However, the histology scores of induced Cugbp1-/- mice fell within 
the mild range.  In these muscles, only 2-3% of the fibers contained central nuclei and these mice had 
minimal fiber size variation and no nuclear clumping (Fig. 5A).Thus the severity of Cugbp1-/-/5-313+/+ 
induced (+dox) mice was milder than the Cugbp1+/+/5-313+/+ (+dox), (P < 0.02, Mann-Whitney U-test).  
Although removal of CUGBP1 did not lead to completely normal muscle histology, it did result in 
significantly improved muscle histopathology.   
We have observed that Nkx2-5 level correlate with severity of the muscle histopathology in DM1 (data 
not shown).  We examined Nkx2-5 levels in Cugbp1+/+/5-313 and Cugbp1-/-/5-313 mice using qRT-PCR.  
Nkx2-5 mRNA levels in the induced Cugbp1+/+/5-313 mouse muscles were dramatically increased, 
whereas the levels were undetectable in the absence of RNA toxicity (Fig. 5C).  However, the induced 
Cugbp1-/- mice had 5 times less Nkx2-5 expression relative to the induced Cugbp1+/+ mice (Fig. 5C).  
Downstream targets of Nkx2-5 like Gata4, Nppa and Nppb (31), were assessed by qRT-PCR and their 
levels were likewise affected (Supp. Fig. S3).   
 
Translational targets of CUGBP1 are also affected in skeletal muscle 
CUGBP1 functions as a translational regulator for several genes such as MEF2A and the C/EBP.  It has 
been reported that transgenic mice over-expressing CUGBP1 have elevated levels of MEF2A and a delay 
in myogenesis (18).  To examine whether the level of these translational targets are affected by the 
presence of RNA toxicity and CUGBP1 status, we analyzed the expression of MEF2A and C/EBP by 
western blotting.  We found that CUGBP1 status had no significant effect on the levels of MEF2A in 
uninduced mice.  However, the level of MEF2A increased in the presence of RNA toxicity in mice 
wildtype for Cugbp1 and this effect was absent in the muscles of Cugbp1-/-/5-313+/+ (+dox) mice (Fig. 
6A).  Likewise, both of the isoforms of C/EBP (LAP and LIP) were consistently increased in 
Cugbp1+/+/5-313+/+ (+dox) mice with RNA toxicity in several independent experiments (Fig. 6B, C).  
Notably, the levels of both the LAP and LIP isoforms were not significantly induced in Cugbp1-/-/5-313+/+ 
(dox+) mice as compared to uninduced mice, and were significantly less than 5-313+/+ (dox+) mice that 
expressed CUGBP1 (Fig. 6B, C).   
 
It has been previously reported that glucocortcoid treatment of mice increased C/EBPin skeletal muscle 
and regulated factors of muscle atrophy, and that knockdown of C/EBP reduced these levels in 
myoblasts (36).  Given the improved muscle histology and decreased levels of C/EBPin the Cugbp1-/-/5-
313 with RNA toxicity, we next analyzed atrogin-1 and MuRF1 mRNA levels in our mouse model.  
Neither toxic RNA nor absence of CUGBP1 influenced atrogin-1 mRNA in our mouse model (data not 
shown).  However, RNA toxicity increased MuRF1 expression and this was alleviated in Cugbp1-/-/5-
313+/+ mice (Fig. 6D).  Thus, absence of CUGBP1 in the toxic RNA model mitigated the effect on 
translational targets like MEF2A and C/EBPwhich are thought to play a role in myogenesis and muscle 
atrophy.   
 
 
Discussion  
Several studies using CUGBP1 transgenic mice support a role for CUGBP1 in DM1 pathogenesis (18-21, 
37).  Transgenic mice over-expressing CUGBP1 reproduced splicing defects observed in individuals with 
DM1 and cardiac or muscle specific expression also showed histological and functional DM1 features 
(19-21).  Recently, a study using a dominant negative CUGBP1 protein showed rescue of splicing defects 
in a cell culture system and a DM1 mouse model (34).  In addition, transgenic mice over-expressing a 
His-tagged CUGBP1 had increased mortality and evidence of disrupted myogenesis, a feature found in 
congenital DM1 (18). 
 These studies also supported the notion that the levels of CUGBP1 have a strong correlation with disease 
severity (18, 21).  Mice with 2-3 fold elevation of His-CUGBP1showed mild histological changes such as 
increased numbers of central nuclei, whereas higher levels (4-6 fold) leads to fiber type switching, fiber 
size variation as well (18).  In another study, using and inducible CUGBP1 transgenic mouse model, an 8-
fold increase in CUGBP1 led to severe histopathology in 4 weeks, whereas a lower induction of CUGBP1 
(2-fold) resulted in very mild muscle pathology (21).  In our mouse model as well as patient tissues, we 
also see a clear correlation between CUGBP1 levels and muscle pathology (Fig. 1).  This suggests that 
reduced levels of CUGBP1 could result in better muscle histology. 
 
As a prelude to performing experiments presented here, we had done a similar series of experiments using 
Cugbp1+/- (i.e. heterozygous knockout mice) and found no significant effects on the measured phenotypes 
or on CUGBP1 levels (data not shown).  So, we examined the consequences of CUGBP1 deficiency in 
RNA toxicity by producing a complete knockout of CUGBP1 in our inducible RNA toxicity model.  The 
absence of CUGBP1 by itself (i.e.  Cugbp1-/- mice) resulted in weak and small mice that had deficits in 
running on a treadmill and in grip strength assays (Fig. 3).  Also, these mice developed cataracts, a 
phenotype commonly seen in patients with DM1 (Supp Fig. 1).  This is unlikely to be related to the 
pathogenesis of cataracts in DM1 since CUGBP1 levels are elevated in DM1, not diminished or absent.  
Notably, absence of CUGBP1 did not lead to myotonia, obvious cardiac conduction defects, or obvious 
histopathology in skeletal muscles; phenotypes that are all prominent in DM1.  However, there was some 
evidence for muscle immaturity based on RNA splicing patterns that resembled a more embryonic 
developmental stage and increased expression of embryonic myosin heavy chain isoforms (Fig. 4).   
Having established a baseline phenotype for the CUGBP1 deficient mice, our goal was to see what effect 
CUGBP1 deficiency would have on our RNA toxicity model.  CUGBP1 has been reported to have 
multiple functions in RNA metabolism including regulation of alternative splicing, RNA stability and 
translational regulation of its RNA targets and a number of molecular events have been associated with 
increased CUGBP1 and RNA toxicity.  Using a systematic analysis of these associated phenotypes, we 
found that absence of CUGBP1 had no obvious effect on the myotonia or cardiac conduction defects 
caused by RNA toxicity.  Surprisingly, disrupted alternative splicing, a key feature of DM1 pathogenesis, 
is not corrected by reduction of CUGBP1.  Not only general targets like Clcn-1 and Tnnt3, but also 
reported CUGBP1 specific targets (Nrap and Fxr1h) are mis-regulated by the toxic RNA even in the 
absence of CUGBP1.  Though CUGBP1 and MBNL1 have been thought of as mutual antagonists, one 
possibility is that MBNL1 may be the stronger and more dominant modulator of alternative splicing 
defects in the RNA toxicity associated with DM1.  Although RNA foci and sequestration of MBNL1 are 
not observed in 5-313 mouse muscle, it is possible that submicroscopic foci exist due to an interaction 
with MBNL1.  Using RNA IP of MBNL1 and associated RNAs, we have found that MBNL1does indeed 
interact with the GFP-DMPK 3’UTR (CUG)5 RNA in our mice and both the normal and mutant DMPK 
mRNAs in human DM1 cell lines (data not shown).  Although we did not see any compensatory effect of 
CUGBP2 or other CELF proteins, it is also possible that the toxic RNA could affect other unknown 
factors that may play a role in RNA splicing in this mouse model.   
 
Though the CUGBP1 deficient mice started off weaker, the fact that there was no further diminution in 
the muscle function tests (treadmill run and grip strength) when RNA toxicity was induced in these mice, 
unlike the mice that were expressing CUGBP1 (Fig. 3), showed that CUGBP1 deficiency preserved 
muscle function despite the effects of RNA toxicity.  Additionally, abnormal muscle histology in mice 
expressing the toxic RNA was restored towards normal, resulting in mice with milder histopathology (Fig. 
5).  Thus absence of CUGBP1 seems to have a clear protective effect against these adverse effects of 
RNA toxicity.  As well, a number of molecular changes caused by RNA toxicity were minimized by the 
absence of CUGBP1.  For instance, it has been previously proposed that the cytoplasmic function of 
CUGBP1 as a translational regulator could be disrupted by RNA toxicity (18).  In this model, it is posited 
that CUGBP1 post-transcriptionally regulated various target mRNAs, such that in DM1, increased 
CUGBP1 in muscle tissue disrupted myogenesis via up-regulation of translational targets such as MEF2A 
(18) and C/EBP (38).  Indeed, in our RNA toxicity model, we see significant elevation of both MEF2A 
and C/EBPβ in skeletal muscle along with an increase in CUGBP1.  Of note, we find that in the absence 
of CUGBP1 in our RNA toxicity mouse model, there is no significant increase in MEF2A and C/EBP 
and that this correlates with a beneficial effect on the histopathology and muscle function.    
 
Though it is unclear how the effects on these translational targets could be affecting muscular dystrophy 
in our model, several recent studies have implicated C/EBPβ in myogenesis and muscle wasting.  In a 
recent study it was found that dexamethasone administration to cultured myoblasts led to increased 
C/EBPβ, upregulated atrogin-1 and MuRF1 and reduced cell size (36).  Treating the myoblasts with a 
siRNA against C/EBPβ resulted in reductions in C/EBPβ and MuRF1and was associated with 
preservation of cell size.  RNA toxicity in our mouse model increases C/EBP and MuRF1 levels in 
skeletal muscle and is associated with muscle weakness, atrophy and histopathology.  Of note, the 
absence of CUGBP1 reduced C/EBPβ and MuRF1 and was associated with decreased atrophy and 
histopathology in our mouse model, analogous to the results from the myoblast study.  Furthermore, 
another group recently reported that C/EBPβ was expressed in satellite cells in skeletal muscle and that 
increased expression of C/EBPβ inhibited satellite cell and C2C12 myoblast differentiation and that loss 
of C/EBP in satellite cells promoted muscle differentiation (39).  This may have relevance to DM1 
muscle histopathology as it has been reported that satellite cell numbers were increased in muscles from 
DM1 patients without a concomitant increase in muscle regeneration, suggestive of a block in satellite 
cell activation or subsequent recruitment into a differentiation program (40).  This is also consistent with 
reports of defects in differentiation and maturation in satellite cells from patients with DM1 (40, 41).   
In summary, CUGBP1 up-regulation clearly correlates with severity of muscle pathology in DM1 patients 
and in our mouse model of RNA toxicity.  However, our data suggests that even complete removal of 
CUGBP1 does not have a significant effect on key phenotypes of DM1 including myotonia, cardiac 
conduction defects and surprisingly, even several splicing defects.  Thus, therapeutic approaches that 
target only CUGBP1 seem likely to have serious limitations, as Cugbp1-/- mice are small and weak and 
key DM1 phenotypes persist even in the absence of CUGBP1.  However, reductions in CUGBP1 did 
have a beneficial effect on muscle histopathology and preservation of muscle function perhaps through 
alterations in the functions of CUGBP1 as a translational regulator.  This suggests that targeting CUGBP1 
could have limited therapeutic benefits with respect to the muscular dystrophy in DM1.  But it is likely 
that this would have to be undertaken in a combinatorial approach with compounds that target MBNL1 
sequestration, or the toxic RNA, or other novel pathways affected by RNA toxicity in patients with DM1. 
 
 
Materials and methods 
Mouse models.   
All animals were used in accordance with protocols approved by the Animal Care and Use Committee 
(ACUC) at the University of Virginia.  DM1 mouse models were generated as previously described (22).  
All progenies were genotyped by PCR.  Six weeks old mice were induced with 0.2 % of doxycycline in 
drinking water.  5-313+/- mice were used for the running and the grip strength test.  The remaining 
experiments used 5-313 +/+ mice. 
 
Protein isolation and western blot.   
Tissues were homogenized in RIPA buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.5% Na 
–deoxycholate, 0.1% SDS) containing protease inhibitor and phosphatase inhibitor.  Protein concentration 
was determined by Bradford assay with 20-40 g of total protein per lane used for western blotting.  
Proteins were detected with antibodes against the following antibodies: CUGBP1 (3B1, EMD Millipore), 
CUGBP2 (N-15, Santa Cruz Biotechnology (SCBT)), MBNL1 (A2764, gift of C.A.  Thornton), MEF2 
(C21, SCBT) and C/EBP (C-19, SCBT). 
 
Treadmill assay and grip strength test.   
Mice were examined for running endurance on a treadmill (Columbus Instruments, OH).  Mice were 
started for 1 min at 10m/min and then ran at the speed of 15m/min for 2 min.  The treadmill accelerated to 
29 m/min at a rate of 2m/min/2min.  After 17min, the treadmill was then increased to 30 m/min for 13min.  
When the mice reached exhaustion (defined as greater than 5 consecutive seconds on the shock grid 
without attempting to re-engage the treadmill), they were removed from the device.  Total time and total 
distance were recorded for each trial (Supp. Table S2). 
Grip strength was measured using a digital grip strength meter, which records the maximal strength an 
animal exerts while trying to resist an opposing pulling force (Columbus Instruments, Columbus, OH).  
Forelimb grip strength was measured using a mouse tension bar.  The results of five consecutive trials on 
the same day were averaged for each animal.  Testers were blind to genotype. 
 
ECGs and EMGs.   
ECG and EMG were measured as described previously (35).  Mice were anesthetized with intraperitonial 
valium (2.5 mg/kg body weight) and ketamine (100 mg/kg body weight) and kept warm during the entire 
procedure.  EMGs were carried out with a TD-20 MK1 EMG machine from TECA, using subdermal 
electrodes for stimulation, and grounding.  Three lead ECG was performed with a BioAmp/Powerlab 
from ADInstrument.  All protocols were approved by and performed under the auspices of the UVA 
Institutional Animal Care and Use Committee. 
 
RNA isolation and RT-PCR.   
Total RNA was extracted from skeletal muscle tissues using TRIzol reagent (Invitrogen).  cDNA was 
synthesized from 1g RNA using QuantiTech Reverse Transcription Kit (Qiagen) and then subjected to 
PCR using gene-specific primers.  After separation on a 1% agarose gel or 10% acrylamide gel, bands 
were quantified using Kodak gel imaging and ImageQuant. 
Quantitative RT-PCR (qRT-PCR) was performed using the BioRad iCycler and detected with 
SYBERGreen dye.  Primer sequence and PCR conditions are given in Supp. Table S3.  All assays were 
done in duplicate, and data normalization was accomplished using an endogenous control (Gapdh).  The 
values were subjected to a 2(-Ct) formula to calculate the fold change between the control and 
experimental groups. 
 
Histology. 
Quadriceps femoris muscles were collected in isopentane and frozen in liquid nitrogen.  Tissues were cut 
at 6m with a cryostat.  Hematoxyline and eosin staining was done according to standard procedures and 
examined under a light microscope.   
 
Statistics 
All data are expressed as mean ± standard deviation.  Statistical significance was determined using a two-
tailed Student's t-test with equal or unequal variance as appropriate.  Mann-Whitney U test was used for 
non-parametric samples and 2 test was used for multinomial samples.  All statistical analyses were 
performed with Microsoft Excel and Minitap16 software.  The significant level was set at P-values less 
than 0.05 for all statistical analyses.   
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Figure Legends 
Figure 1.  CUGBP1 levels correlate with muscle histopathology in skeletal muscles of patients with 
DM1 and in the 5-313 mice.  Graded muscle tissues from (A) human samples and (B) the 5-313 mouse 
model were subjected to western blot for CUGBP1.  CUGBP1 levels increased with severity of muscle 
histopathology in both DM1 individuals and the 5-313 mice.  GAPDH was used as loading control.   
 
Figure 2.  Molecular characterization of RNA-binding proteins.  Protein extracts were prepared from 
skeletal muscle tissues of mice and examined by western blots.  CUGBP1 was not detected in Cugbp1-/- 
mice.  Western blot for CUGBP2, MBNL1 showed no change due to absence of CUGBP1 or presence of 
RNA toxicity.  Western blot for eGFP confirmed transgene induction.  GAPDH was used as loading 
control.   
 
Figure 3.  Preservation of muscle function in Cugbp1 -/-/5-313+/- mice.  Cugbp1+/+/5-313+/- mice (n=7) 
and Cugbp1-/-/5-313+/- mice (n=5) were induced with 0.2% of doxycycline for 5 months.  Uninduced mice 
were used as control (Cugbp1+/+/5-313+/- (n=4), Cugbp1-/-/5-313+/- (n=3)).  (A) Mice were subjected to 
treadmill running and distance run was measured.  The measurements were converted to % retained, as 
compared to a baseline measurement for each mouse.  (B) Grip strength was assessed using a grip 
strength meter.  Data were expressed as force in grams and converted to % of grip-strength retained as 
compared to baseline.  Significant differences were **P < 0.01 and ***P < 0.005 (t-test). 
 
Figure 4.  Absence of CUGBP1 has no beneficial effects on the RNA splicing defects caused by RNA 
toxicity.  (A) ClCn-1 exon 7a, Tnnt3-fetal exon and Smyd1 exon 39 were analyzed as mRNA splicing 
targets of DM1.  (B) Nrap exon 12 and Fxr1h exons15-16 were assessed as CUGBP1 specific targets.  
Both Cugbp1+/+/5-313 and Cugbp1-/-/5-313 mice were tested in uninduced (-dox) and induced (+dox) 
conditions (n=5 per group).  The percentage of exon inclusion is graphically represented.  (C) Expression 
of embryonic myosin heavy chain (Myh3) was examined by qRT-PCR.  Significant differences were *P 
< 0.05, **P < 0.01 and ***P < 0.005 (t-test).   
 
Figure 5.  Improved Muscle Histopathology in CUGBP1-/-/5-313 and correlation with levels of 
Nkx2-5 mRNA.  (A) Quadrceps femoris mucles were stained with hematoxylin and eosin.  Both 
uninduced Cugbp1+/+/5-313 and Cugbp1-/-/5-313 mice have normal muscle histology.  Cugbp1-/-/5-313 
(+dox) mice have milder histopathology compared to Cugbp1+/+/5-313(+dox) mice.  (B) Histopathology 
grading shows Cugbp1-/- has a beneficial effect (n=5); **P < 0.002 (Mann-Whitney U test).  (C) Nkx2-5 
mRNA level was assessed by qRT-PCR and relative expression is presented.  Cugbp1-/-/5-313 mice 
(+dox) have five times less Nkx2-5 mRNA than Cugbp1+/+/5-313 mice (+dox) (n=5); **P < 0.01 (t-test). 
 
Figure 6.  MEF2A and C/EBP protein levels and expression of MuRF1 mRNA are affected by 
absence of CUGBP1 in RNA toxicity.  (A)Western blot for MEF2A.  Numbers indicate relative 
intensity of bands (n=4).  Increased protein levels from Cugbp1+/+/5-313 (+dox) are significantly reduced 
in Cugbp1-/-/5-313 (+dox) mice (P < 0.05).  (B) C/EBP LAP and (C) LIP isoforms were measured from 
western blots and relative protein expression are graphically represented.  Both LAP and LIP levels were 
increased by RNA toxicity in induced 5-313 mice but not in Cugbp1-/-/5-313 mice (n=5 per group).  (D) 
Relative MuRF1 mRNA expressions were measured by qRT-PCR.  Cugbp1+/+/5-313(+dox) mice (n=6) 
have five fold more MuRF1 mRNA than uninduced mice (n=7) and these levels are reduced to 1.6 fold in 
Cugbp1-/-/5-313(+dox) (n=5).  *P < 0.05, **P < 0.01 and ***P < 0.005 (t-test). 
 
 
